6T-CEM Acute lymphocytic leukemia; Human (CRL-8296)

Designation / Description 6T-CEM Acute lymphocytic leukemia; Human
U.S. Patent Number
Biosafety Level 2

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

This is a 6-thioguanine resistant variant of CCRF-CEM.
It is deficient in hypoxanthine phosphoribosyl transferase (HPRT, HGPRT) and secretes high titers of an immunosuppressive factor.
This line may be used as a fusion partner for making human T cell hybridomas.
immunosuppressive factor
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Handle as potentially biohazardous material under at least Biosafety Level 2 containment.
Shipped frozen
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation

Lau CY. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor. US Patent 4,705,687 dated Nov 10 1987